scholarly journals Intraperitoneal administration of 5-fluorouracil microspheres against peritoneal carcinomatosis in rodents.

1997 ◽  
Vol 12 (2) ◽  
pp. 95-100 ◽  
Author(s):  
Junya Yamasaki ◽  
Akeo Hagiwara ◽  
Toshio Takahashi ◽  
Shozo Muranishi ◽  
Yoshito Ikada
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Administration

Treatment of peritoneal carcinomatosis with intraperitoneal administration of Ad-hARF

2015 ◽  
Vol 197 (1) ◽  
pp. 85-90
Author(s):  
Barur R. Rajeshkumar ◽  
Seema Paliwal ◽  
Laura Lambert ◽  
Steven R. Grossman ◽  
Giles F. Whalen
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Administration

scholarly journals Reduction of peritoneal carcinomatosis by intraperitoneal administration of phospholipids in rats

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Jens Otto ◽  
Petra Lynen Jansen ◽  
Stefan Lucas ◽  
Volker Schumpelick ◽  
Marc Jansen
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Administration

Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients

2014 ◽  
Vol 73 (5) ◽  
pp. 1009-1020 ◽  
Author(s):  
Carlos Pérez-Ruixo ◽  
José E. Peris ◽  
Vanesa Escudero-Ortiz ◽  
Pedro Bretcha-Boix ◽  
José Farré-Alegre ◽  
...  
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Administration

scholarly journals STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer

2021 ◽  
Vol 9 (6) ◽  
pp. e002195
Author(s):  
Seung Joon Lee ◽  
Hannah Yang ◽  
Woo Ram Kim ◽  
Yu Seong Lee ◽  
Won Suk Lee ◽  
...  
Keyword(s):  
Colon Cancer ◽  
T Cell ◽  
Peritoneal Carcinomatosis ◽  
Peritoneal Dissemination ◽  
Intraperitoneal Administration ◽  
Immune Checkpoints ◽  
Type I ◽  
Dependent Manner ◽  
Immune Microenvironment ◽  
Cell Functions

BackgroundPeritoneal carcinomatosis is a fatal clinical presentation of colon cancer, characterized by unresponsiveness to conventional anticancer therapies, including immune checkpoint inhibitors. Here, we elucidated the immune-evasion mechanisms during the peritoneal carcinomatosis of colon cancer and developed a novel immunotherapy by activating the stimulator of interferon genes (STING) pathway.MethodsWe generated a syngeneic peritoneal carcinomatosis model of colon cancer. Mice were intraperitoneally treated with either STING agonist (MIW815, also known as ADU-S100) or PD-1 blockade or both. The tumor microenvironment was comprehensively analyzed using multiplexed immunofluorescence imaging, flow cytometry, and NanoString immune profiling.ResultsIntraperitoneal colon cancer cells induce a massive influx of immunosuppressive M2-like macrophages, upregulate immune checkpoints, and impair effector T cell functions during peritoneal dissemination; these collectively create a highly angiogenic and immunosuppressive milieu that is resistant to anti-PD-1 monotherapy. Intraperitoneal administration of a STING agonist suppressed aberrant angiogenesis, increased pericyte coverage, and normalized tumor vessels, thereby facilitating the infiltration of activated CD8+ T cells into peritoneal tumor nodules. Moreover, STING activation reprogramed tumor-associated macrophages toward the M1 phenotype. STING activation converted immunologically cold peritoneal tumors into T-cell-inflamed tumors in a type-I interferon-dependent manner. Lastly, the STING agonist synergistically cooperated with PD-1 and/or COX2 blockade to further suppress the peritoneal dissemination of colon cancer, resulting in complete eradication of tumor and ascites, and inducing durable antitumor immunity.ConclusionsSTING activation can normalize the peritoneal vascular and immune microenvironment, providing a rationale for a novel combination therapeutic strategy for peritoneal carcinomatosis in colon cancer.

Sign in / Sign up

Export Citation Format

Share Document